Silk Fibroin/Polycaprolactone Coaxial Nanofibrous Scaffold Loaded with Kaempferol and Icariin: A Bioactive Macromolecular Platform for Bone Regeneration through Enhanced Antibacterial Activity and Osteoimmunomodulation
Yuhui Liu, Ning Zhou, Yumeng Luo, Xinyue Guan, Wenxin Meng, Xing Yu, Quanli Li, Qunlin Zhang, Xianwen Wang, Guomin WuAbstract
This study aims to fabricate a scaffold based on natural herbal active substances, achieving antibacterial, anti-inflammatory, and osteogenic activities by graded and sustained drug release, overcoming the high cost and instability of growth factors in conventional bone defect scaffolds. Coaxial electrospinning was employed to construct a scaffold with silk fibroin (SF)/polycaprolactone (PCL)/kaempferol (KAE) as the shell and icariin (ICA) as the core, preparing nanofibrous scaffolds (ICA@SF/PCL/KAE). Comprehensive characterizations confirmed the co-axial structure of the nanofibers and successful drug loading and favorable release profiles of KAE and ICA, as well as the significantly enhanced mechanical performance. The KAE-loaded scaffold exerted outstanding antibacterial activity, while all of the drug-containing scaffolds maintained excellent cytocompatibility. In LPS-induced inflammatory environments, macrophages co-cultured on KAE-containing scaffolds exhibited markedly reduced reactive oxygen species and nitric oxide production, along with a decreased M1 macrophage ratio and an increased M2 macrophage ratio. RT-PCR results demonstrated that KAE-loaded scaffolds downregulated pro-inflammatory gene expression and upregulated anti-inflammatory gene expression. In vitro osteogenic induction revealed that the incorporation of KAE and ICA, especially ICA, remarkably enhanced osteogenic activity of the nanofibrous scaffolds. Under inflammatory conditions, KAE-containing scaffolds exhibited superior regulation of the osteogenic immune microenvironment compared with ICA-containing scaffolds. Notably, the ICA@SF/PCL/KAE scaffold containing both components achieved the optimal performance in all of the above in vitro experiments. Finally, rat cranial defect experiments further verified the excellent osteogenic efficacy of ICA@SF/PCL/KAE in vivo. Collectively, the ICA@SF/PCL/KAE core–shell nanofibrous scaffold offers an innovative approach for clinical bone defect treatment and expands the application potential of natural herbal active substances.